Testing atezolizumab for recurrent glioblastoma
Treatments studied
Part of Cancer clinical trials.
This trial tests whether the immunotherapy drug atezolizumab can help people with glioblastoma that has come back after initial treatment. You will need to have a biopsy before starting the drug to confirm the tumor has returned.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with glioblastoma (a type of brain cancer) that is not linked to the IDH gene mutation.
- Your tumor has come back for the first or second time after radiation and temozolomide chemotherapy.
- You have enough stored tumor tissue from your original diagnosis.
- Your organs (like kidneys, liver, and blood cells) are working well enough based on blood tests.
- You are able to take care of yourself for at least 70% of the day (Karnofsky score of 70% or higher).
- You are not pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation, an immunotherapy drug (sintilimab), and chemotherapy (temozolomide) for people with glioblastoma that has come back. The goal is to see if this approach can help control the tumor and improve survival.
This trial tests a combination of MRI-guided laser surgery, a wearable device (Optune) that sends electric fields to the brain, and an immunotherapy drug (pembrolizumab/Keytruda) for people whose glioblastoma has come back. The goal is to see if this approach is safe and works better than standard treatments.
This trial tests a combination of immunotherapy (retifanlimab), a targeted drug (bevacizumab), and low-dose radiation for people whose glioblastoma has come back. The goal is to see if this treatment can help shrink or slow the tumor.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This early study looks at a treatment plan (including resection/surgery and an added medicine) for glioblastoma that has come back after standard therapy. The goal is to see how well it controls tumor growth and whether it is tolerable.
This early-stage trial tests a new drug called YSCH-01, alone or combined with an immunotherapy drug (atezolizumab), for glioblastoma that has come back after previous treatment. The study places a small tube in the brain to deliver the drug directly and monitors safety and how well it works.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.